The authors only mentioned the opportunity to perform transthoracic US (TUS)-guided biopsies. It is mandatory to underline that TUS has to be considered a valuable tool in detecting even small lesions adherent to the pleural surface. [2] The low complications rate is not only due to the correct patients' selection, as highlighted in the paper, [1] but also to the correct technique, the use of an atraumatic semi-automatic needle (20-gauge) and a dedicated probe. [2] The procedure-related complications with TUS guidance are less frequent than reported in the review. [1] It has been already published that in 856 fine-needle aspiration biopsy (FNAB) performed, only four patients had a self-limiting pneumothorax (0.4%), and no major complications have been reported. [3] In another case series, [4] in 95 TUS-guided FNAB, there was no pneumothorax or hemorrhagic pleural effusion.
It is advisable the use of a dedicated probe, that is, with a central hole through which the needle set is introduced. [4] This is still the most suitable and reliable approach for these purposes because the needle is visible in real time during the biopsy. Transducers with "parallel" needle guidance allow only oblique access, with the needle angulated versus the US beam, causing some uncertainty of localization.
Under TUS guidance, it is also possible to choose the right needle size, generally an atraumatic 20-gauge. The technique used is called "modified Menghini." It consists of a needle with stylet connected to a syringe plunger; the needle tip is Menghini type, whereas the stylet tip is pyramidal. This provides specimens suitable for histologic diagnosis and minimizes the occurrence of complications, which appear to be more frequent with 18-gauge needles [1] [ Figure 1 ].
Moreover, TUS guidance allows to perform biopsies even at the bedside; this could be useful in patients with low-performance status.
In conclusion, TUS-guided FNAB should be the "first choice" as a diagnostic procedure in pleural and adherent to pleura pulmonary lesions. [5] Financial support and sponsorship
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We thank the authors of the letter for their interest and the comments on our paper published in a recent issue of Annals of Thoracic Medicine. [1] Emphasizing the valuable role of the US-guided transthoracic needle aspiration (US-TTNA) for investigating pleural-based nodules is in absolute concordance with the message of our paper. However, from a clinical standpoint, we would like to stress that the key to increase the diagnostic accuracy and decrease the complications rate is the correct patients' selection.
In our paper, the reported pneumothorax rate of 4.4% of the US-TTNA is a pooled analysis from a systematic review which involved 10 relevant studies. [2] The 0.4% complications rate of self-limiting pneumothorax reported using a specific technique that includes a dedicated US probe with a central hole and a semi-automated (20-gauge) modified Menghini type needle is impressive; [3] however, this technique is not universally available nor universally applicable and further research is required to confirm these very promising results.
In conclusion, sampling peripheral lesions are often challenging, and the choice of the best approach should be individualized according to the specific characteristics of the patient and the lesion. Every available modality should be examined in that process to achieve the best possible care for our patients. 
